Skip NavigationSkip to Content

Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints

  1. Author:
    Alexander,Patrick
    Chan,Albert
    Rabara,Dana
    Swain,Monalisa
    Larsen,Erik
    Dyba,Marcin
    Chertov,Oleg
    Ashraf, Mariam
    Champagne,Alysia
    Lin, Ken
    Maciag,Anna
    Gillette,William
    Nissley,Dwight
    McCormick, Frank
    Simanshu,Dhirendra
    Stephen,Andrew
  2. Author Address

    NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., BridgeBio Oncology Therapeutics, South San Francisco, CA, USA., Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA. Electronic address: stephena@nih.gov.,
    1. Year: 2025
    2. Date: Jun 03
    3. Epub Date: 2025 06 03
  1. Journal: The Journal of Biological Chemistry
    1. Pages: 110331
  2. Type of Article: Article
  3. Article Number: 110331
  1. Abstract:

    RAS mutations are observed in 20% of all cancers, with the KRAS isoform highly mutated in colorectal, lung and pancreatic cancers. The last several years have seen the development of clinical compounds that target KRAS G12C mutations, with other compounds under clinical development. In this study, a series of KRAS small-molecule inhibitors were compared for their binding affinity against a panel of KRAS mutant alleles. These inhibitors either covalently target the G12C mutant or reversibly target other mutants by binding in a transient pocket known as the switch-II pocket. Covalent inhibitors bound KRAS-GDP with KD values ranging from 10-9-10-3 M, whereas reversible inhibitors bound in the low nM range. A loss of affinity was observed for KRAS-GppNHp, due in part to rearrangements in switch-II, where the hydrogen bond between G60 and the gamma-phosphate needs to break to form the switch-II pocket. Interestingly, these inhibitors had reduced affinity to KRAS Q61R-GppNHp, but not to WT and other mutants. The crystal structure of KRAS Q61R-GppNHp reported here revealed that access to the switch-II pocket was restricted due to R61 forming an additional hydrogen bond with the backbone carbonyl of T35 in switch-I. The restricted access to the switch-II pocket caused a decrease in the association rate of inhibitor binding and resulted in a loss of affinity. These findings across KRAS mutants provide valuable insights into the conformational adaptability of the switch-II pocket and may prove useful in developing the next generation of allele-specific and pan-KRAS small molecule inhibitors. Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.jbc.2025.110331
  2. PMID: 40473215
  3. PII : S0021-9258(25)02181-7

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel